Farallon Capital Management’s Forte Biosciences FBRX Stock Holding History

Farallon Capital Management’s Portfolio FBRX Stock Details FBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-70,429	Closed	-$547K	–	152
2025 Q1	$547K	Buy	70,429 +35,429	+101%	+$418K	﹤0.01%	95
2024 Q4	$795K	Sell	35,000 -37,413	-52%	-$445K	﹤0.01%	99
2024 Q3	$406K	Sell	72,413 -5	-0%	-$51	﹤0.01%	112
2024 Q2	$972K	Hold	72,418	–	–	﹤0.01%	108
2024 Q1	$1.27M	Hold	72,418	–	–	0.01%	118
2023 Q4	$1.49M	Hold	72,418	–	–	0.01%	102
2023 Q3	$1.2M	Buy	+72,418	New	+$1.61M	0.01%	111
2017 Q3	–	Sell	-267	Closed	-$1.2M	–	88
2017 Q2	$1.2M	Buy	+267	New	+$1.5M	0.01%	81

Other funds holding FBRX

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

TCM

Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

CCC

Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Farallon Capital Management's FBRX Position: Q2 2025 in Review

Farallon Capital Management sold out of Forte Biosciences (FBRX) in Q2 2025, closing a stake of 70,429 shares — an estimated $547K sold.

Farallon Capital Management first reported a position in FBRX in Q2 2017 and held it in 8 quarters. The position peaked at $1.49M in Q4 2023. 33 funds tracked by Wall St. Rank hold FBRX as of Q2 2025.

Farallon Capital Management reported no remaining Forte Biosciences position as of Q2 2025 after selling out during the quarter.
Farallon Capital Management sold 70,429 Forte Biosciences shares in Q2 2025, an estimated $547K.
Farallon Capital Management first reported a position in Forte Biosciences in Q2 2017 and held it in 8 quarters.
Farallon Capital Management's Forte Biosciences position peaked at $1.49M in Q4 2023.
33 funds tracked by Wall St. Rank held Forte Biosciences as of Q2 2025.

Based on Farallon Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.